Maximizing patient impact in oncology: R&D strategies

In our weekly expert view, head of oncology at German pharma company Bayer, Robert LaCaze looks at the evolution of cancer treatments over the past two decades and looks ahead to what the future might look like.

Within the last two decades we all have seen the huge advances that have been made in oncology treatment options and new paradigms of treatments.

But, despite the significant progress, far too many of the 33 million people living with cancer today lack viable treatment options. Data show that this number is expected to sharply climb over the next two decades.